Neuregulin‑1: An underlying protective force of cardiac dysfunction in sepsis (Review)

Abstract

neuregulin-1 (nrG-1) is a type of epidermal growth factor-like protein primarily distributed in the nervous and cardiovascular systems. When sepsis occurs, the incidence of cardiac dysfunction in myocardial injury is high and the mechanism is complicated. it directly causes myocardial cell damage, whilst also causing damage to the structure and function of myocardial cells, weakening of endothelial function and coronary microcirculation, autonomic dysfunction, and activation of myocardial inhibitory factors. Studies investigating nrG-1 have been performed using a variety of methods, including in vitro models, and animal and human clinical trials; however, the results are not consistent. nrG-1

Serum levels of neuregulin-1 in patients with coronary artery disease: clinical and pathogenetic aspects

“…или экспрессии NRG-1 приводит к ухудшению восстановления сократительной функции сердца после повреждения [3]. Существует ряд работ по изучению терапевтического потенциала NRG-1 при различных сердечно-сосудистых заболеваниях.…”

“…Существует ряд работ по изучению терапевтического потенциала NRG-1 при различных сердечно-сосудистых заболеваниях. Продемонстрировано его непосредственное влияние на кардиомиоциты, эндотелиальные клетки, макрофаги и фибробласты, приводящее к активной пролиферации клеток, антиапоптозу, противовоспалительному и антиоксидантному эффектам, а также регулирующей роли в процессах энергетического метаболизма миокарда [1][2][3][4]. При этом работы по изучению роли NRG-1 у пациентов с ишемической болезнью сердца (ИБС) крайне малочисленны [5,6], а данные, полученные авторами, весьма противоречивы, в связи с чем представляется актуальным изучение концентрации NRG-1 у пациентов с различной выраженностью атеросклеротического поражения коронарных артерий (КА), в т.ч.…”

Nrg1β as a Proangiogenesis Therapy: How Is Nrg1β Therapy Unique From Other Angiogenesis Therapies?

“…However, it is well known that excessive inflammation can cause detrimental effects in the infarcted heart. 27 In this context, Nrg1β-ErbB2 signaling may play a unique role in proangiogenesis therapy after acute MI because it has an anti-inflammatory role, 15,[28][29][30] and its proangiogenic capacity does not rely on its proinflammatory effects (Figure). It is important to emphasize that the initial inflammatory response after MI is critical for promoting the healing process after ischemic injury but that excessive inflammation can be detrimental, as explained above.…”

Neuregulin-1, a member of the epidermal growth factor family, mitigates STING-mediated pyroptosis and necroptosis in ischaemic flaps

“…Growth factor treatments offer benefits such as promoting tissue repair and regeneration, expediting healing, improving treatment outcomes and enabling personalized therapy [ 19 , 20 ]. Neuregulin-1 (NRG1) is an epidermal growth factor-like protein primarily found in the nervous and cardiovascular systems and is considered a key driver of tissue regeneration in multiple organs [ 21 ]. In hind-limb ischaemia models, NRG1 has been identified as a crucial mediator of angiogenesis [ 20 ], while its activation during myocardial injury protects against microvascular endothelial damage and reduces oxidative stress and cell death [ 22 , 23 ].…”